Skip to main content
    C

    Celcuity LLC (CELC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $60.30
    +0.40 (+0.67%)

    Market Cap: $2.97B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(19/36)
    Avg Surprise
    -8.01%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.51
    Range$-1.60 - $-1.42
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.08-39.2%
    60d ago$-1.08-39.2%
    30d ago$-1.18-28.0%
    7d ago$-1.18-28.0%
    Current$-1.51
    Revenue Consensus
    $2M
    Range$0 - $4M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.91
    Range$-1.00 - $-0.82
    2 analysts
    Revenue Consensus
    $21M
    Range$5M - $56M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.91---
    Sep 26EST
    		-$-1.51---
    Jun 26
    Reported Aug 13
    		$-1.44$-1.08-33.33%Miss-54.8%
    Mar 26
    Reported May 14
    		$-0.86$-0.89+3.37%Beat-6.2%
    Dec 25
    Reported Mar 25
    		$-0.73$-1.05+30.48%Beat+2.7%
    Sep 25
    Reported Nov 12
    		$-0.78$-0.96+18.75%Beat-20.0%
    Jun 25
    Reported Aug 14
    		$-0.93$-0.84-10.71%Miss-60.3%
    Mar 25
    Reported May 14
    		$-0.81$-0.86+5.81%Beat-26.6%
    Dec 24
    Reported Mar 31
    		$-0.75$-0.67-11.94%Miss-23.0%
    Sep 24
    Reported Nov 14
    		$-0.65$-0.70+7.14%Beat+16.7%
    Jun 24
    Reported Aug 14
    		$-0.58$-0.55-5.45%Miss+0.0%
    Mar 24
    Reported May 15
    		$-0.64$-0.71+9.86%Beat-36.2%
    Dec 23
    Reported Mar 27
    		$-0.61$-0.75+18.67%Beat+11.6%
    Sep 23
    Reported Nov 13
    		$-0.78$-0.53-47.17%Miss-4.0%
    Jun 23
    Reported Aug 10
    		$-0.58$-0.46-26.09%Miss-5.5%
    Mar 23
    Reported May 15
    		$-0.47$-0.43-9.30%Miss+11.3%
    Dec 22
    Reported Mar 23
    		$-0.69$-0.44-56.82%Miss-86.5%
    Sep 22
    Reported Nov 10
    		$-0.75$-0.60-25.00%Miss-114.3%
    Jun 22
    Reported Aug 11
    		$-0.55$-0.48-14.58%Miss+16.7%
    Mar 22
    Reported May 16
    		$-0.53$-0.51-3.92%Miss-152.4%
    Dec 21
    Reported Mar 23
    		$-0.37$-0.35-5.71%Miss-76.2%
    Sep 21
    Reported Nov 8
    		$-0.35$-0.24-45.83%Miss-45.8%
    Jun 21
    Reported Aug 9
    		$-0.66$-0.21-214.29%Miss-288.2%
    Mar 21
    Reported May 10
    		$-0.21$-0.20-5.00%Miss-23.5%
    Dec 20
    Reported Feb 16
    		$-0.21$-0.22+4.55%Beat-50.0%
    Sep 20
    Reported Nov 9
    		$-0.24$-0.23-4.35%Miss-50.0%
    Jun 20
    Reported Aug 10
    		$-0.17$-0.18+5.56%Beat-13.3%
    Mar 20
    Reported May 7
    		$-0.17$-0.17+0.00%Beat-6.3%
    Dec 19
    Reported Mar 12
    		$-0.14$-0.18+22.22%Beat+6.7%
    Sep 19
    Reported Nov 7
    		$-0.16$-0.17+5.88%Beat-6.7%
    Jun 19
    Reported Aug 8
    		$-0.15$-0.18+16.67%Beat+0.0%
    Mar 19
    Reported May 7
    		$-0.16$-0.20+20.00%Beat+0.0%
    Dec 18
    Reported Feb 26
    		$-0.15$-0.18+16.67%Beat-7.1%
    Sep 18
    Reported Nov 13
    		$-0.15$-0.18+16.67%Beat+25.0%
    Jun 18
    Reported Aug 9
    		$-0.15$-0.17+11.76%Beat-36.4%
    Mar 18
    Reported May 14
    		$-0.16$-0.19+15.79%Beat-
    Dec 17
    Reported Mar 15
    		$-0.14$-0.15+6.67%Beat-
    Sep 17
    Reported Nov 13
    		$-0.20$-0.19-5.26%Miss-
    Jun 17
    Reported Sep 20
    		$-0.11N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-15.83EV/EBITDAN/A
    Price/FCF-17.20xFCF Yield-5.81%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1434.00%ROIC-19.78%
    Financial Health
    Debt/Equity-58.95xInterest Coverage-5.29x
    Current Ratio8.93xQuick Ratio8.93x
    Trading Statistics
    Beta0.11Avg Volume1.41M
    52-Week High$151.0252-Week Low$49.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$66.78
    SMA 20$73.35
    SMA 50$83.62
    SMA 200$102.86
    EMA 10$66.52
    EMA 20$71.88
    EMA 50$80.95
    EMA 200$90.01

    MACD

    Line: -6.51Signal: -5.40Hist: -1.11

    ADX

    ADX: 29.4+DI: 13.0-DI: 37.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$73.95

    Bollinger Bands

    Upper Band$88.78
    Lower Band$57.93
    %B Position4206%(Upper)
    Band Width0.08

    RSI (14-Day)

    Oversold
    24.7

    Momentum Oscillators

    Stoch %K2.9
    Stoch %D6.0
    Williams %R-95.6
    ROC (10d)-19.7%
    Momentum-14.83
    CCI (20d)-131.8
    MFI (14d)24.2

    Volatility Measures

    ATR (14d)$4.33(7.2%)
    StdDev (20d)7.71
    Hist Vol53.2%(High)

    Volume Flow

    VWAP$60.68
    OBV47.5M
    AD Line-28.6M
    CMF (20d)-0.293

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio1.4x
    VWMA (20d)$71.11

    Pivot Points

    R3$67.03
    R2$65.24
    R1$62.57
    Pivot Point$60.77
    S1$58.11
    S2$56.31
    S3$53.64

    Advanced Oscillators

    TSI-41.67
    Ultimate Osc33.1
    KST-218.93

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$154,000$0$0$121,344$0$0$0$229,648$0
    Cost of RevenueN/A$47,000N/A$41,000$40,000$37,000$35,254$34,021$31,115$29,557$27,948$33,555
    Gross ProfitN/A$-47,000N/A$-41,000$-40,000$-37,000$-35,254$-34,021$-31,115$-29,557$-27,948$-33,555
    Operating Expenses$66.12M$50.46M$49.20M$42.85M$44.01M$36.13M$36.39M$30.06M$24.28M$22.49M$19.70M$18.90M
    R&D$31.08M$33.06M$37.63M$34.91M$40.22M$32.23M$33.47M$27.59M$22.50M$20.65M$18.08M$17.49M
    SG&A$35.04M$17.44M$11.57M$7.93M$3.79M$3.91M$2.96M$2.47M$1.79M$1.85M$1.65M$1.41M
    Operating Income$-66,118,000$-50,507,000$-49,201,000$-42,849,000$-44,009,000$-36,133,000$-36,430,131$-30,059,899$-24,284,000$-22,493,000$-19,729,272$-18,898,037
    Interest Income$4.15M$3.75M$4.39M$3.64M$1.95M$2.32M$3.05M$3.61M$2.82M$2.28M$2.28M$1.87M
    Interest Expense$5.42M$6.08M$6.17M$17.37M$3.20M$3.18M$3.28M$3.34M$2.26M$1.40M$1.40M$1.37M
    Income Before Tax$-78,864,000$-52,841,000$-50,973,000$-43,804,000$-45,268,000$-36,997,000$-36,653,041$-29,791,789$-23,722,000$-21,612,000$-18,848,472$-18,404,540
    Income Tax Expense$0$0$0$0$0$0$-3$0$-5$3$2$1.91M
    Net Income$-78,864,000$-52,841,000$-50,973,000$-43,804,000$-45,268,000$-36,997,000$-36,653,041$-29,791,789$-23,722,000$-21,612,000$-18,848,472$-18,404,540
    EBITDA$-54,582,000$-46,709,000$-44,758,000$-39,168,000$-42,024,000$-33,777,000$-33,342,626$-26,413,800$-21,431,000$-20,181,000$-17,423,277$-16,998,853
    EBIT$-54,641,000$-46,756,000$-44,807,000$-39,209,000$-42,064,000$-33,814,000$-33,377,880$-26,447,800$-21,462,000$-20,211,000$-17,451,225$-17,032,408
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CELC

    News

    how InvestingPro’s Fair Value flagged Celcuity’s 52% decline By Investing.com

    InvestingPro's Fair Value analysis accurately flagged Celcuity (NASDAQ:CELC) as severely overvalued in May 2026 when it was trading at $138.23. Despite some positive developments...

    Investing.com•10/13/26•Bearish

    Form 4 Celcuity LLC For: 11 October By Investing.com

    This article provides a brief notice about a Form 4 filing for Celcuity LLC, pertaining to October 11. Form 4 filings are typically used to report changes in beneficial ownership of securities by company insiders....

    Investing.com South Africa•10/12/26•Neutral

    Form 4 Celcuity LLC For: 11 October By Investing.com

    This article from Investing.com reports on a Form 4 filing for Celcuity LLC, dated October 11. Form 4 filings are legally required documents submitted to the SEC in the United States...

    Investing.com Canada•10/11/26•Neutral

    Precision Trading with Celcuity Inc. (CELC) Risk Zones

    This article from Stock Traders Daily provides a detailed analysis of Celcuity Inc. (CELC), highlighting weak near and mid-term sentiment and a neutral long-term outlook with elevated downside risk. It presents three...

    Stock Traders Daily•10/10/26•Somewhat-Bearish

    Does REVTORPYK Launch Change The Bull Case For Celcuity Stock?

    Celcuity has launched commercial sales of REVTORPYK in the US for advanced breast cancer, shifting its focus from clinical development to commercial execution. This move places scrutiny on its sales, cost base...

    Simply Wall Street•10/10/26•Somewhat-Bullish

    CELC Valuation and Fair Value

    P/E
    -15.8x
    P/FCF
    -17.2x
    P/B
    -258.6x
    See GNG's fair value

    CELC Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -19.8%
    ROE
    -1434.0%
    FCF yield
    -5.8%

    CELC Competitors

    CompanyTicker
    Warby Parker IncWRBY
    Enliven Therapeutics Inc.ELVN
    Ideaya Biosciences IncIDYA
    Denali Therapeutics IncDNLI
    Arcutis Biotherapeutics IncARQT
    Arcus Biosciences IncRCUS
    Xenon Pharmaceuticals IncXENE
    Soleno Therapeutics IncSLNO

    Sector: Healthcare

    CELC Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    3
    Buy
    9
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CELC Bull Case vs Bear Case

    Bull case

    • 100.0% of CELC's analyst ratings are Buy or Strong Buy.

    CELC Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    1.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.51
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About CELC

    Does CELC pay dividends?

    Celcuity LLC (CELC) does not currently pay a regular dividend.

    What is CELC's market cap?

    Celcuity LLC (CELC) has a market capitalization of $2.97B with a current stock price of $60.30.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In